{"id":900540,"date":"2026-09-15T08:31:26","date_gmt":"2026-09-15T06:31:26","guid":{"rendered":"https:\/\/intervacc.se\/?p=900540"},"modified":"2026-09-15T08:31:26","modified_gmt":"2026-09-15T06:31:26","slug":"intervacc-to-present-at-upcoming-international-healthcare-conference","status":"publish","type":"post","link":"https:\/\/intervacc.se\/en\/intervacc-to-present-at-upcoming-international-healthcare-conference\/","title":{"rendered":"Intervacc to present at upcoming International Healthcare Conference"},"content":{"rendered":"<div class=\"preamble\">\n<p><em>Intervacc AB (publ), a growth company in veterinary medicine with its vaccine Strangvac<sup>\u00ae<\/sup> registered in 16 European countries, today announces participation in an international Healthcare conference:<\/em><\/p>\n<\/div>\n\n\n<!--more-->\n\n\n\n<p><strong>Swiss Nordic Bio Conference 2026<\/strong><br>Location: Radisson Blue Hotel, Zurich Airport<br>Format: Presentation and 1-on-1<br>Participation date: October 1<br>Participant: Carl-Johan Dalsgaard, CEO<\/p>\n\n\n\n<p><strong>For more information please contact:<\/strong><br>Carl-Johan Dalsgaard, VD<br>Phone: +46 (0)8 120 10 600<br>E-mail: carl-johan.dalsgaard@intervacc.se<\/p>\n\n\n\n<p><em>The information was submitted for publication, through the agency of the contact person set out above on September 15, 2026 at 08.30 CET.<\/em><\/p>\n\n\n\n<p><strong>About Strangvac<\/strong><br>Strangvac<sup>\u00ae<\/sup> is a vaccine against the severe disease equine strangles. The vaccine is approved for sales and marketing in the EU as well as the UK, Iceland, Norway and Liechtenstein, and has been launched in Sweden, Denmark, Finland, the UK, France, Germany, Belgium, the Netherlands, Austria, Spain, Portugal, Ireland, Poland, Slovenia and Italy.<\/p>\n\n\n\n<p><strong>About Intervacc<\/strong><br>Intervacc AB is an animal health group that develops vaccines for animals. The company\u2019s vaccines and vaccine candidates are based on many years of research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The Intervacc share (Nasdaq: IVACC) is listed on the Nasdaq First North Growth Market. For more information, visit intervacc.se<\/p>\n\n\n\n<p><strong>Contact information for Certified Adviser<\/strong><br>Eminova Fondkommission AB<br>E-mail: adviser@eminova.se, Phone: +46 (0)8 \u2013 684 211 10<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Intervacc AB (publ), a growth company in veterinary medicine with its vaccine Strangvac\u00ae registered in 16 European countries, today announces [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[33],"tags":[],"_links":{"self":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/900540"}],"collection":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=900540"}],"version-history":[{"count":10,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/900540\/revisions"}],"predecessor-version":[{"id":900647,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/900540\/revisions\/900647"}],"wp:attachment":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=900540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/categories?post=900540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/tags?post=900540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}